Expression and clinical significance of CD163 in hepatic fibrosis with biliary atresia

doi:10.11958/20221539

Abstract

Abstract:

Objective To investigate the expression of CD163 in children with biliary atresia (BA) and its relationship with liver fibrosis. Methods A total of 30 children with BA (the BA group, 14 patients with liver fibrosis grade Ⅰ-Ⅱ, 16 patients with liver fibrosis grade Ⅲ-Ⅳ) and 10 children with choledochal cyst (the CC group) were collected. Samples of liver tissue and blood were obtained from the 2 groups. The expression levels of CD163 in liver tissue and blood of the two groups were detected by immunohistochemistry and flow cytometry. The expression of sCD163 was detected by enzyme-linked immunosorbent assay (ELISA), and the value of sCD163 in evaluating BA liver fibrosis was analyzed by receiver operating characteristic curve (ROC). Results Immunohistochemical staining and flow cytometry indicated that CD163 expression levels in liver tissue and blood were significantly higher in the BA group than those in the CC group (P<0.01), and which increased with the increased severity of liver fibrosis (P<0.01). The expression of sCD163 also showed the same change. sCD163 predicted BA with an area under the ROC curve of 0.927, a best threshold value of 8.323 μg/L, a sensitivity of 86.67% and a specificity of 100%. Conclusion The expression of CD163 is up-regulated in children with BA, which accelerates the process of liver fibrosis. sCD163 can accurately reflect the severity of liver fibrosis in children with BA.

Key words: biliary atresia, hepatic fibrosis, CD163

CLC Number:

R726

Figures/Tables 4

Fig.1 IHC results of CD163 expression in liver tissue of the CC group and the BA group (×200)

Fig.2 FCM results of CD163 expression in blood of the CC group and the BA group

Fig.3 Evaluation of ROC curve of BA liver fibrosis evaluated by sCD163

Tab.1 Biochemical indexes related to liver function in BA grade Ⅰ-Ⅱ and grade Ⅲ~Ⅳ liver fibrosis

组别	n	ALT （U/L）	AST （U/L）	TB （μmol/L）	DB （μmol/L）
Ⅰ~Ⅱ级	14	112（76，149）	165（129，266）	174.0±33.0	141.9±28.3
Ⅲ~Ⅳ级	16	116（96，180）	225（147，303）	166.2±44.6	133.0±31.5
Z或t		0.644	1.102	0.528	0.816

References 20

[1]	UDOMSINPRASERT W, POOVORAWAN Y, CHONGSRISAWAT V, et al. Decreased circulating clusterin reflects severe liver complications after hepatoportoenterostomy of biliary atresia[J]. Sci Rep, 2020, 10(1):19736. doi:10.1038/s41598-020-76875-9.
[2]	詹江华, 李梦迪. 胆道闭锁Kasai术后胆管炎的发病机制探讨[J]. 天津医药, 2022, 50(1):1-4.
	ZHAN J H, LI M D. The study on pathogenesis of cholangitis after Kasai procedure in children with biliary atresia[J]. Tianjin Med J, 2022, 50(1):1-4. doi:10.11958/20211092.
[3]	WANG Y, RAO H, CHI X, et al. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality[J]. EBioMedicine, 2019, 46:227-235. doi:10.1016/j.ebiom.2019.07.043.
[4]	LAURSEN T L, WONG G L, KAZANKOV K, et al. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment[J]. J Gastroenterol Hepatol, 2018, 33(2):484-491. doi:10.1111/jgh.13849.
[5]	GRØNBÆK H, RØDGAARD-HANSEN S, AAGAARD N K, et al. Macrophage activation markers predict mortality in patients with liver cirrhosis without or with acute-on-chronic liver failure (ACLF)[J]. J Hepatol, 2016, 64(4):813-822. doi:10.1016/j.jhep.2015.11.021.
[6]	丁美云, 詹江华, 刘丹丹, 等. 胆道闭锁肝纤维化分级[J]. 中华小儿外科杂志, 2015, 36(11):866-872.
	DING M Y, ZHAN J H, LIU D D, et al. Grading of hepatic fibrosis in biliary atresia[J]. Chin J Pediatr Surg, 2015, 36(11):866-872. doi:10.3760/cma.j.issn.0253-3006.2015.11.016.
[7]	SHEN W J, CHEN G, WANG M, et al. Liver fibrosis in biliary atresia[J]. World J Pediatr, 2019, 15(2):117-123. doi:10.1007/s12519-018-0203-1.
[8]	BOLTJES A, MOVITA D, BOONSTRA A, et al. The role of Kupffer cells in hepatitis B and hepatitis C virus infections[J]. J Hepatol, 2014, 61(3):660-671. doi:10.1016/j.jhep.2014.04.026.
[9]	陈灵芝, 詹江华, 赵金凤, 等. 磷脂酰肌醇蛋白多糖3对胆道闭锁患儿的诊断价值及与肝纤维化的关系[J]. 天津医药, 2022, 50(1):15-19.
	CHEN L Z, ZHAN J H, ZHAO J F, et al. The diagnostic value of glypican 3 in children with biliary atresia and its relationship with liver fibrosis[J]. Tianjin Med J, 2022, 50(1):15-19. doi:10.11958/20211114.
[10]	余晨, 熊希倩, 詹江华, 等. MMP-7在胆道闭锁肝纤维化患者中的表达及临床意义[J]. 天津医药, 2019, 47(1):38-42.
	YU C, XIONG X Q, ZHAN J H, et al. Expression and clinical significance of MMP-7 in hepatic fibrosis of biliary atresia[J]. Tianjin Med J, 2019, 47(1):38-42. doi:10.11958/20181302.
[11]	ZHAO J, XU X, GOU Q, et al. TGF-β1-mediated leukocyte cell-derived chemotaxin 2 is associated with liver fibrosis in biliary atresia[J]. Front Pediatr, 2022, 10:901888. doi:10.3389/fped.2022.901888.
[12]	DULTZ G, GERBER L, FARNIK H, et al. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus[J]. J Viral Hepat, 2015, 22(4):427-432. doi:10.1111/jvh.12309.
[13]	ZHAO S X, LI W C, FU N, et al. CD14+ monocytes and CD163+ macrophages correlate with the severity of liver fibrosis in patients with chronic hepatitis C[J]. Exp Ther Med, 2020, 20(6):228. doi:10.3892/etm.2020.9358.
[14]	BELJAARS L, SCHIPPERS M, REKER-SMIT C, et al. Hepatic localization of macrophage phenotypes during fibrogenesis and resolution of fibrosis in mice and humans[J]. Front Immunol, 2014, 5:430. doi:10.3389/fimmu.2014.00430.
[15]	KAZANKOV K, BARRERA F, MØLLER H J, et al. Soluble CD163,a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C[J]. Hepatology, 2014, 60(2):521-530. doi:10.1002/hep.27129.
[16]	GANTZEL R H, KJÆR M B, LAURSEN T L, et al. Macrophage activation markers, soluble CD163 and mannose receptor, in liver fibrosis[J]. Front Med (Lausanne), 2020, 7:615599. doi:10.3389/fmed.2020.615599.
[17]	刘更新, 詹江华. 胆道闭锁诊断方法价值分析[J]. 中华肝胆外科杂志, 2021, 27(3):232-235.
	LIU G X, ZHAN J H. Analysis of diagnostic value of biliary atresia[J]. Chinese Journal of Hepatobiliary Surgery, 2021, 27(3):232-235. doi:10.3760/cma.j.cn113884-20200416-00203.
[18]	CHEN X, DONG R, SHEN Z, et al. Value of gamma-glutamyl transpeptidase for diagnosis of biliary atresia by correlation with age[J]. J Pediatr Gastroenterol Nutr, 2016, 63(3):370-373. doi:10.1097/MPG.0000000000001168.
[19]	LERTUDOMPHONWANIT C, MOURYA R, FEI L, et al. Large-scale proteomics identifies MMP-7 as a sentinel of epithelial injury and of biliary atresia[J]. Sci Transl Med, 2017, 9(417):eaan8462. doi:10.1126/scitranslmed.aan8462.
[20]	SCHREIBER R A. Newborn screening for biliary atresia[J]. JAMA, 2020, 323(12):1137-1138. doi:10.1001/jama.2020.2727.